Palvella Therapeutics, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities
Palvella Therapeutics, Inc. (PVLA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities of $3.14 million as of 2024-12-13, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Liability Assumed, Liability › Business Combination, Recognized Liability Assumed, Liability, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities · last filed 2026-03-31
- 2024-12-13: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities $3.14M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities |
|---|---|
| 2024-12-13 | $3.14M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |